2002

Viral induction of a chronic asthma phenotype and genetic segregation from the acute response

Michael J. Walter  
Washington University School of Medicine in St. Louis

Jeffrey D. Morton  
Washington University School of Medicine in St. Louis

Naohiro Kajiwara  
Washington University School of Medicine in St. Louis

Eugene Agapov  
Washington University School of Medicine in St. Louis

Michael J. Holtzman  
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation  
Walter, Michael J.; Morton, Jeffrey D.; Kajiwara, Naohiro; Agapov, Eugene; and Holtzman, Michael J., "Viral induction of a chronic asthma phenotype and genetic segregation from the acute response." The Journal of Clinical Investigation.110,2. 165-175. (2002). https://digitalcommons.wustl.edu/open_access_pubs/1429
Viral induction of a chronic asthma phenotype and genetic segregation from the acute response

Michael J. Walter,1 Jeffrey D. Morton,1,2 Naohiro Kajiwara,1 Eugene Agapov,1 and Michael J. Holtzman1,2,3

1Pulmonary and Critical Care Medicine, Department of Medicine,
2Program in Immunology, and
3Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA

Paramyxoviral infections cause most of the acute lower respiratory tract illness in infants and young children and predispose to the development of chronic wheezing, but the relationship between these short- and long-term viral effects are uncertain. Here we show that a single paramyxoviral infection of mice (C57BL6/J strain) not only produces acute bronchiolitis, but also triggers a chronic response with airway hyperreactivity and goblet cell hyperplasia lasting at least a year after complete viral clearance. During the acute response to virus, same-strain ICAM-1-null mice are protected from airway inflammation and hyperreactivity despite similar viral infection rates, but the chronic response proceeds despite ICAM-1 deficiency. Neither response is influenced by IFN-γ deficiency, but the chronic response is at least partially prevented by glucocorticoid treatment. In contrast to viral infection, allergen challenge caused only short-term expression of asthma phenotypes. Thus, paramyxoviruses cause both acute airway inflammation/hyperreactivity and chronic airway remodeling/hyperreactivity phenotypes (the latter by a hit-and-run strategy, since viral effects persist after clearance). These two phenotypes can be segregated by their dependence on the ICAM-1 gene and so depend on distinct controls that appear critical for the development of lifelong airway diseases such as asthma.

newly described yet invariant feature of asthma: an intrinsically abnormality in cell programming of the airway epithelium toward an anti-viral Th1 response (26). In particular, airway epithelial cells are specially programmed with anti-viral networks, and the behavior of these cells in asthma resembles a persistent anti-viral response (27–31). It is also not certain how the Th2 hypothesis reconciles its insights into the allergic response — a short-term response — with the development of a lifelong disease.

In that context, a relationship between viral infection and the development of chronic inflammatory disease has been proposed for diverse clinical syndromes, but the mechanistic basis for this relationship is still uncertain. Relevant to asthma, paramyxoviral infections are the leading cause of lower respiratory tract illness in infants and young children (32, 33), and children with clinically significant viral bronchiolitis appear to be marked for the subsequent development of a chronic wheezing illness that is independent of allergy (34). Presumably paramyxoviral infection triggers an abnormal host response, since paramyxoviruses (and other respiratory RNA viruses) are not thought to persist in airway tissue as an ongoing stimulus of chronic respiratory disease (35). In either case (i.e., with or without viral persistence), the role of specific host factors in the development of acute or chronic wheezing or lifelong asthma still remains to be determined.

To better define viral and host factors in the development of the asthma phenotype, we took advantage of a mouse model of paramyxoviral bronchiolitis with acute pathology similar to the human condition (31). Thus, mouse parainfluenza virus type 1 (Sendai virus; SeV) at proper inoculum causes infection limited to the airway mucosa and inflammation largely restricted to peribronchial/bronchiolar tissues. We reasoned that inhibition of the acute inflammatory response could be achieved by targeted disruption of airway epithelial immune-response genes. These genes form a network that is directly induced by viral replication and is dominated by an array of IFN-responsive genes (27, 29, 31). Among candidate genes that might mediate immune cell traffic, ICAM-1 is the predominant determinant for adhesion of immune cells (especially T cells) to epithelial cells in vitro (28, 36, 37). Indeed, in the present experiments conducted in vivo, we found that ICAM-1 expression is induced primarily on host airway epithelial cells by viral infection and is necessary for full development of acute inflammation and concomitant postviral airway hyperreactivity. Unexpectedly, however, we also found that primary viral infection causes a persistent asthma phenotype (i.e., airway hyperreactivity, goblet cell hyperplasia, and mucin production) despite ICAM-1 deficiency, and this phenotype is maintained despite clearance of virus. This phenotype is also inductible by allergen challenge, but in this case, the phenotype resolves spontaneously with time. In the context of previous data, the findings establish the capacity of a single paramyxoviral infection to cause both acute and chronic manifestations of the phenotype for hypersecretory airway disease and define the relevance of specific host defense genes in moderating the acute, but not necessarily the chronic, phenotype. In addition, the results provide initial evidence of the capacity for nononcogenic riboviruses (i.e., paramyxovirus) to irreversibly reprogram host cell behavior in a manner previously restricted to oncogenic DNA viruses (38, 39). These findings therefore raise the possibility that asthma not only resembles a persistent anti-viral response (30, 31) but may even be caused by such a response, and so provide the experimental link between paramyxoviral infection in infancy with subsequent asthma in childhood and perhaps adulthood.

Methods

Mouse generation and housing. Wild-type C57BL/6J and same-strain IFN-γ-null mice were obtained from The Jackson Laboratory (Bar Harbor, Maine, USA) (40). Same-strain ICAM-1-null mice were a generous gift from J.-C. Gutierrez-Ramos (Millennium Pharmaceuticals Inc., Cambridge, Massachusetts, USA) directly and via The Jackson Laboratory (41). IFN-γ- and ICAM-1-null mice were backcrossed for nine and ten generations, respectively, onto the C57BL/6J strain. The ICAM-1–null mice are interrupted in ICAM-1 gene exon 4 to avoid generation of alternatively spliced isoforms that may still interact with lymphocyte function antigen-1 (42). Thus, anti–ICAM-1 mAb 3E2 recognizes all five ICAM-1 isoforms and does not detect ICAM-1 in this strain (ref. 41 and data not shown). Mice were maintained under pathogen-free conditions for study at 7–9 weeks of age. Experimental manipulations were performed in a class II laminar flow hood. Sentinel mice and experimental control mice were handled identically to inoculated mice and exhibited no serologic or histologic evidence of exposure to 11 rodent pathogens (including SeV).

Viral inoculation and monitoring. After ketamine/xylazine anesthesia, mice were inoculated intranasally with the indicated dose (50% egg infectious dose, EID50) of SeV (Fushimi strain) or with UV-inactivated SeV in 30 µl PBS. The viral expression level in lung tissue was monitored by immunostaining and Western blotting with anti-SeV Ab (31), viral plaque assay (43), and real-time quantitative RT-PCR using a fluorogenic probe/primer combination for SeV nucleocapsid protein RNA (nucleotides 519–587 in GenBank accession M30202) according to the manufacturer’s protocol (PE Biosystems, Foster City, California, USA). Lung RNA was extracted with TRIzol (Invitrogen Corp., Grand Island, New York, USA) and the RNeasy mini kit (QIAGEN Corp., Valencia, California, USA). The extracted RNA was then subjected to RT-PCR using the TaqMan One-Step system (PE Biosystems) to detect viral negative- and positive-strand RNA. Synthetic RNA standards for nucleocapsid protein and control GAPDH were generated from portions of the nucleocapsid protein gene (nucleotides 10–620) and GAPDH gene.
(nucleotides 37–910) cloned into pCR2.1 (Invitrogen Corp., Carlsbad, California, USA) and were in vitro transcribed using T7 MEGAscript (Ambion Inc., Austin, Texas, USA). Standards were purified by TRIZol extraction, DNase treatment (three rounds), RNeasy mini kit preparation (three rounds), and phenol extraction, and then run in duplicate serial dilutions to construct standard curves and calculate the copy number of virus-specific RNA in experimental samples.

**Histochemistry.** Mouse lung (at 25 cm H2O pressure) was fixed in 10% buffered formalin, dehydrated in ethanol, embedded in paraffin, and cut into 5-µm-thick sections. To detect ICAM-1, tissue sections were blocked with 5% nonimmune goat serum and then incubated sequentially with hamster anti–mouse ICAM-1 IgG mAb (2 µg/ml of clone 3E2 from Pharmingen, San Diego, California, USA), biotinylated goat anti-hamster IgG (7.5 µg/ml), streptavidin-conjugated horseradish peroxidase, and 3,3′-diaminobenzidine chromagen (Vector Laboratories Inc., Birmingham, California, USA). Sections were also immunostained for MUC5AC mucin and underwent amylase digestion and Alcian blue/periodic acid–Schiff (PAS) staining as indicators of mucus production and corresponding levels of goblet cells (44). For MUC5AC immunostaining, tissues were blocked with mouse IgG (Vector Laboratories Inc.) and then incubated with mouse anti–human MUC5AC mAb 45M1 (2 µg/ml; Lab Vision Corp., Fremont, California, USA). Tissue sections were counterstained with hematoxylin, dehydrated in graded ethanol, and mounted for photomicrography and quantification of reporter by cell counting (cells per mm of basement membrane), area of epithelium (percentage of total epithelial area calculated using Image-Pro Express version 4: Media Cybernetics, Carlsbad, California, USA), and epithelial staining intensity (calculated using Optimas version 5; Optimas Corp., Bothell, Washington, USA) as described previously (30, 31).

**Bronchoalveolar lavage fluid analysis.** Bronchoalveolar lavage was performed via tracheal cannulation with an aliquot of 0.8 ml of sterile PBS with 2% FBS. Each sample was subjected to hypotonic lysis, cytosin centrifugation, and Wright-Giemsa staining, and was then used for total and differential cell counts.

**Airway reactivity measurements.** Airway reactivity to aerosolized methacholine was determined using a single-chamber whole-body plethysmograph and BioSystem XA version 1.5.7 software (Buxco Electronic Inc., Sharon, Connecticut, USA) to derive values for enhanced pause (Penh) as described previously (45). Mice were placed in the plethysmograph for a 5-minute acclimatization interval, followed by 5-minute acquisition intervals before (baseline Penh) and after 3-minute exposure to nebulized vehicle (PBS) or doubling concentrations of methacholine (5–160 mg/ml) delivered from a Collison 6 jet nebulizer (BGI Inc., Waltham, Massachusetts, USA).

**Allergen challenge.** C57BL/6J mice were sensitized and then challenged with antigen using a method modified from one described previously (46). Mice were immunized by intraperitoneal injection of ovalbumin (Ova; 8 µg) adsorbed to aluminum hydroxide gel (1 mg) in 0.5 ml PBS at 3 weeks before challenge (study day –21), and were given an identical booster immunization 2 weeks before challenge (day –14). Mice were challenged with PBS or Ova (2 mg) in PBS (50 µl) given intranasally as described above for viral inoculation. Challenges were performed with intranasal PBS or Ova either twice (12 hours apart) on day 0 (for a total of two challenges) or twice on day 0 and again once on days 1 and 2 (for a total of four challenges). On days 3, 21, and 77 after initial challenge, all mice were assessed for airway reactivity and goblet cell hyperplasia as described above.

**Statistical analysis.** Values for bronchoalveolar lavage fluid cell counts, weight losses, Western blots, and viral titers were analyzed using the unpaired Student t test. Values for Penh and histochemistry of mouse tissues were analyzed using a one-way ANOVA for a factorial experimental design. If significance was achieved by one-way analysis, comparison of means after ANOVA was performed using Scheffe’s F test. The significance value for all analyses was 0.05.

**Results**

ICAM-1–null mice are protected against airway inflammation after SeV bronchiolitis. Initial experiments indicated that SeV inoculation with 50–50,000 EID50 caused a spectrum of illness ranging from no detectable effect (at 50 EID50) to reversible bronchiolitis (at 5,000 EID50) to lethal bronchopneumonia (at 50,000 EID50) in the C57BL/6J genetic background (ref. 31 and data not shown). We therefore used SeV inoculation at 5,000 EID50 for further experiments aimed at modeling viral bronchiolitis in humans. With this inoculum, SeV replication and induction of ICAM-1 expression were colocalized predominantly to bronchiolar epithelium (Figure 1a). Wild-type and ICAM-1–null mice responded to this level of infection with immune cell infiltration confined to sites of viral replication, but ICAM-1–null mice responded with fewer immune cells, especially neutrophils and lymphocytes (Figure 1, b and c). This phenotypic pattern is consistent with in vitro findings, i.e., in airway epithelial cell monolayers, where ICAM-1 gene expression is inducible by paramyxoviral infection and is required for leukocyte adhesion and transmigration (28, 29, 36, 37, 47). These findings are also consistent with evidence of decreased inflammation after loss of ICAM-1 in several other models, including allergen challenge (48). However, others report little change in neutrophil influx induced by Streptococcus pneumoniae or Klebsiella pneumoniae (49, 50), perhaps reflecting alternative mechanisms for immune cell recruitment and/or activation in response to bacterial infection in the lung.

The blunted inflammatory response in ICAM-1–null mice was beneficial to the host since this cohort experienced less weight loss after bronchiolitis (Figure 2a).
and lower mortality rates after SeV bronchopneumonia (data not shown). In addition, the decrease in airway inflammation did not appear to hamper host defense, since initial viral infection rate and subsequent clearance was not significantly altered in ICAM-1–null versus wild-type control mice (Figure 2, b–d). Clearance by 12–21 days after SeV infection is consistent with previous reports that assess viral titer by endpoint titration in embryonated hen eggs (51–53), but the present data using real-time RT-PCR also provides evidence against persistence of viral genome in the host tissue as mutant quasispecies of virus (54).

ICAM-1–null mice are protected against acute but not chronic airway hyperreactivity after SeV bronchiolitis. We have long proposed that airway inflammation may lead to airway hyperreactivity (55), so we determined whether ICAM-1–null mice (which are relatively protected from virus-induced airway inflammation) are also protected from postviral hyperreactivity. For these experiments, we used whole-body barometric plethysmography to measure Penh as an index of airway obstruction at baseline and after methacholine challenge in wild-type and ICAM-1–null mice inoculated with SeV, UV-inactivated SeV, or vehicle alone. In this setting, we found slightly increased baseline Penh and airway reactivity by 7 days after inoculation with SeV in both types of mice (Figure 3). Baseline Penh returned to normal in both types of mice by 14 days after inoculation, but airway reactivity was increased markedly by this time in wild-type mice. Moreover, the development of postviral hyperreactivity at this timepoint and at 21 days after inoculation was significantly diminished in ICAM-1–null mice. Methacholine-induced increases in Penh were rapidly and fully reversible by treatment with inhaled albuterol, and so were consistent with airway smooth muscle contraction and consequent bronchoconstriction (data not shown).

These findings linked virus-inducible inflammation with hyperreactivity via the ICAM-1 gene during the first 21 days after infection, but continued monitoring indicated that hyperreactivity recurred at maximal levels by 77 days after infection in ICAM-1–null mice, and persisted throughout the monitoring period in wild-type mice (Figure 3). In fact, virus-inducible hyperreactivity proceeded unchanged for at least a year (see below). Thus, ICAM-1 deficiency protects to at least some degree against acute inflammation (maximal at 8 days) and subacute airway hyperreactivity (maximal...
at 21 days) but does not protect at all against the chronic hyperreactivity (manifest at 77 days and longer) that develops in response to SeV infection in this genetic background. Many previous reports indicate that respiratory viral infection may transiently increase airway reactivity in animal models and humans (56), but the present findings indicate that viral infection may also permanently reprogram airway reactivity.

Chronic airway hyperreactivity is accompanied by airway remodeling after SeV bronchiolitis. Recognizing that the host epithelial cell is a primary target of viral infection, we next determined whether infection also resulted in persistent changes in epithelial behavior. Indeed, airway hyperreactivity developed in concert with prominent airway epithelial remodeling that was fully manifest by 21 days and was maintained to a similar degree at 77 days after SeV infection in wild-type or ICAM-1–null mice (Figure 4). In particular, we observed a marked increase in PAS-positive cell staining in a pattern indicative of goblet cell hyperplasia in the airway epithelium. The increase in PAS-positive cells was matched by increased immunostaining for the mucin MUC5AC, indicating upregulation of mucus-producing goblet cells. Quantifying this phenotype confirmed that ICAM-1 deficiency was not protective against chronic goblet cell hyperplasia, just as it was not protective against long-term airway hyperreactivity. However, in the case of goblet cell hyperplasia, ICAM-1 deficiency did not exert even transient protection at 21 days after SeV infection,
suggesting separate controls for the development of the two components (hyperreactivity and remodeling) of the chronic asthma phenotype as well.

IFN-$\gamma$–/– mice and wild-type mice exhibit similar acute and chronic responses. As noted above, epithelial ICAM-1 gene expression is selectively sensitive to IFN-$\gamma$ in vitro and in vivo, but is still sensitive to viral induction in vitro using epithelial monolayers that exclude IFN-$\gamma$–producing cell types (27, 36, 47, 57–59). Thus, the relative roles of IFN-$\gamma$ (derived from immune cells) versus other endogenous mediators produced directly by epithelial cells for driving ICAM-1 expression in vivo were still undefined. In the present experiments, we found that viral induction of ICAM-1 expression proceeded unchanged in IFN-$\gamma$–null mice, suggesting that epithelial pathways for ICAM-1 expression respond directly to viral infection without a requirement for IFN-$\gamma$ that is derived from immune cells. In addition, IFN-$\gamma$–null mice exhibited levels of weight loss, mortality, viral protein, and airway inflammation that were no different from those in wild-type control mice (Figure 5, a and b, and data not shown). These findings are consistent with the preservation of the CTL response and normal SeV clearance in the absence of IFN-$\gamma$ in the BALB/cJ genetic background (52). The correlation between ICAM-1 expression, airway inflammation, and airway reactivity was reinforced in these experiments when we found that wild-type and IFN-$\gamma$–null mice both exhibited similar increases in acute and chronic airway reactivity as well (Figure 5c). In both cohorts, airway hyperreactivity was maintained at the same levels for at least a year after viral clearance, in concert with the same persistent degree of goblet cell hyperplasia (Figure 6, a and b).

Comparison to the allergic response. To determine whether the virus-induced phenotype was typical of other asthmagenic stimuli, we next monitored the airway response to allergen over an extended time period in this setting. We used a protocol that depended on allergen sensitization and subsequent challenge with Ova, since that allergen has been so extensively studied in murine models of asthma. In the present experiments, Ova challenge caused smaller increases in airway reactivity but a similar degree of goblet cell hyperplasia compared with viral

Figure 4
Persistence of goblet cell hyperplasia after viral infection in wild-type and ICAM-1–null mice. (a) Wild-type and ICAM-1–null mice were inoculated with SeV (5,000 EID$_{50}$) or SeV-UV, and lung sections were stained with PAS and immunostained for MUC5AC mucin. Representative photomicrographs are shown for each genotype ($n = 5$) at postinoculation day 21. Immunostaining with nonimmune IgG gave no signal above background (data not shown). Bar, 20 $\mu$m. (b) Quantification of results shown in a using values for MUC5AC$^+$ cells per mm basement membrane (bm) and for MUC5AC$^+$ staining as percentage of total epithelial area. Values represent mean ± SEM ($n = 10$ airways from three to five mice). Similar results were found by analysis of staining intensity (data not shown). (c) Wild-type and ICAM-1–null mice were inoculated with SeV or SeV-UV and subjected to analysis on postinoculation day 77 as described in a and b. Representative photomicrographs and corresponding quantification are shown for MUC5AC immunostaining for each genotype ($n = 5$). Bar, 50 $\mu$m. Results for PAS staining were similar to results at postinoculation day 21 (data not shown). (d) Quantification of results shown in c. Values represent mean ± SEM. No significant difference was detected for postinfection values for wild-type versus ICAM-1–null or for postinfection day 21 versus day 77. *Significant increase from control SeV-UV.
infection (Figure 7). However, in contrast to the response to viral infection, allergen-induced phenotypes were fully developed by day 3 after challenge, were decreasing by day 21, and were resolved by day 77. These observations were consistent with previous studies of Ova immunization and challenge in mice (45, 46, 60), but the present data provide a more complete description for the resolution of the allergic response. In addition, the present results for Ova and SeV derive from mice of the same genetic background (C57BL/6J) to exclude the possibility that this was the basis for short- versus long-term effects of allergen versus viral infection.

**Response to treatment with glucocorticoid.** Previous work has indicated that asthma and allergen-induced asthma in experimental models is sensitive to glucocorticoid treatment (24, 60). Accordingly, we next determined whether the virus-induced asthma phenotypes were responsive to glucocorticoid treatment. Using a protocol for glucocorticoid administration that began after viral clearance but before airway remodeling, we found that the chronic remodeling/hyperreactivity phenotype was at least partially prevented by treatment with glucocorticoids (Figure 8, a and b). As discussed below, these findings are consistent with similar events in glucocorticoid-treated subjects with asthma.
We reported previously that asthma is characterized by persistent activation of the bronchial epithelium in a pattern that is similar to one inducible by viral infection (28, 30, 31). These findings suggested that an abnormal response to virus might contribute to asthma pathogenesis (reviewed in ref. 26), but it was also possible that the epithelial response was driven by other inflammatory stimuli. For example, allergen inhalation might also lead to epithelial activation indirectly via Th cell cytokine production, and under some circumstances even this response may require Th1 cytokines that are more typical of anti-viral responses (15, 61). In addition, the previous data focused on the acute immune response to virus and so could not fully account for the persistent changes in epithelial behavior that occur in a chronic disease such as asthma. In that context, the present study offers the critical information that a single paramyxoviral infection has the capacity to cause not only the acute manifestations of the asthma phenotype but also results in long-lasting changes in airway behavior that are characteristic of asthma. In addition, we demonstrate that the acute and chronic responses can be genetically segregated, since the acute but not the chronic response is influenced by genetics.

**Figure 7**
Reversibility of airway hyperreactivity and goblet cell hyperplasia after allergen challenge. (a) On the indicated study days, wild-type mice were sensitized to Ova, then challenged with intranasal PBS or Ova either twice on day 0 (Ova ×2) or twice on day 0 and again on days 1 and 2 (Ova ×4), and finally were phenotyped for airway hyperreactivity and goblet cell hyperplasia. (b) For each experimental condition, airway reactivity was assessed as described in legends for Figure 3 and Figure 5. (c) For the same conditions, lung sections were immunostained for MUC5AC mucin, and immunopositive cells were quantified as described in Figure 4 legend. For b and c, all values represent mean ± SEM for groups of eight to ten mice. *Significant change from the corresponding PBS-challenged cohort.
Glucocorticoid suppression of airway hyperreactivity and goblet cell hyperplasia after viral infection in mice. (a) Wild-type mice were inoculated with SeV (5,000 EID$_{50}$) or SeV-UV and then treated with saline or dexamethasone (0.5 mg/kg per day, given subcutaneously) on postinoculation days 13–21. At the end of this period, levels of airway hyperreactivity were determined as described in Figure 3 legend. (b) For the same conditions described in (a), MUC5AC+ cells were determined as described in Figure 4 legend. For (a) and (b), all values represent mean ± SEM. n = 10 mice. *Significant decrease compared with saline-treated cohort. GC, glucocorticoid.

The Journal of Clinical Investigation | July 2002 | Volume 110 | Number 2

173
however, these studies have focused on the acute response to virus, and the relevance of this mechanism for chronic persistent changes must still be defined.

Taken together, the present findings establish the capacity of a single paramyxoviral infection to permanently change epithelial behavior and airway reactivity in a pattern that is remarkably similar to one in asthma. The present results add to previous findings indicating that paramyxoviral infection and asthma may activate a network of epithelial immune-response genes that are part of the innate immune response (28, 30, 31). Thus, we now find that paramyxoviral infection may also lead to chronically abnormal airway structure and function, with goblet cell hyperplasia and airway hyperreactivity that is typical of asthma and other hypersecretory airway diseases. Furthermore, this chronic phenotype can be genetically segregated from the acute anti-viral response in mice. Several gene products appear to regulate goblet cell hyperplasia after allergen exposure, fitting a paradigm in which Th2 products (e.g., IL-4, IL-5, IL-9, and IL-13) may upregulate while Th1 products (e.g., IFN-γ) downregulate the response (75, 76). Further studies will be required to precisely identify the genes responsible for epithelial remodeling and chronic hyperreactivity in response to paramyxoviral infection, but the lack of IFN-γ-dependent regulation in this setting implies that the viral pathway is distinct from pathways driven by allergen. Indeed, the present results raise the possibility that primary paramyxoviral infection in a specific genetic background may lead to chronic dysfunction of host cell behavior that overlaps with but does not depend on allergy (26).

Acknowledgments

The authors gratefully acknowledge Robert Arch, Guang Fan, Michelle Jenkerson, Peter Karanja, William Roswit, and Holly Toennies for assistance and advice. This research was supported by grants from NIH (Heart, Lung, and Blood Institute), the American Lung Association, the Martin Schaeffer Fund, and the Alan A. and Edith L. Wolff Charitable Trust.

References

20. Corry, D.B., et al. 1995. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactiv-

27. Taguchi, M., et al. 1998. Patterns for RANTES secretion and intercellu-
tutive activation of an epithelial signal transducer and activator of tran-
33. Sigurs, N. 2001. Epidemiologic and clinical evidence of a respiratory syn-


